Oncology Market Expertise and Global Contacts   I  Accredited CME for Oncologists  I   Provider Number: CPDSO 50212

Skip to navigation Skip to content
Oncology Market Expertise
Oncology Commercial Services
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact

Tag: multiple-authors

Tag: multiple-authors

Breast cancer risk-factors and benefits of early screening

By AnnaH

Although breast cancer is the most common type of female cancer throughout the Middle East, many women do not seek medical care promptly. Consequently, the region has increased rates of late incidences. Dr Marwan Elbagouray explains breast cancer risks and the benefits of early screening.

Read More

Posts pagination

  • Previous
  • 1
  • …
  • 9
  • 10
Recent Posts
  • Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
  • Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
  • Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
  • Daiichi Sankyo and AstraZeneca does a Batman & Robin act and fires off its second ADC shot of 2024 with another FDA BLA for Dato-DXd
  • Is it time for PET-guided therapy in follicular lymphoma?
×

Error: Contact form not found.

Back To Top

  • Home
  • Team
  • Advisory Services
  • Market Intelligence Services
  • Recruitment
  • Contact
  • Market Access / BD
  • CME Learner Resources
  • CME Evaluation Form
  • Help Centre
  • Contact
  • Disclaimers
  • Privacy & GDPR Policy
  • Website Accessibility Policy
  • Equal Opportunities Policy and Learning Charter
  • Complaints Policy
  • Contact
© Oncology Commercial Services 2025
Built with Storefront.

Copyright 2024  Oncology Commercial Services. All Rights Reserved. Fratrem Group Ltd, Company number 08002465